Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01052272 · ClinicalTrials.gov registry record · Phase 2
Impact of Diabetes on Left Ventricular Remodeling
A Phase 2 study, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- Phase 2
- Development phase
- 72
- Enrollment target
NCT01052272 is a Phase 2 study that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 72 participants.
The verdict
NCT01052272, a Phase 2 study, has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 72 participants
- Enrollment target
Study Summary
The investigators hypothesize that in patients with diabetes and acute myocardial infarction (MI), Ang II type-1 receptor blockade (AT1RB) attenuates left ventricle (LV) remodeling to a greater extent than angiotensin converting enzyme (ACE) inhibitor therapy and that the addition of xanthine oxidase (XO) inhibitor, Allopurinol, results in further improvement in LV remodeling and function in the follow-up phase after MI.
Interventions
- DRUG Allopurinol
- DRUG Ramipril
- DRUG Candesartan cilexetil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2005-07 |
| Est. Completion | 2010-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01052272
The ClinicalTrials.gov registry entry for NCT01052272 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Allopurinol is the first listed.
NCT01052272 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01052272 about?
NCT01052272 is a clinical study titled "Impact of Diabetes on Left Ventricular Remodeling". The investigators hypothesize that in patients with diabetes and acute myocardial infarction (MI), Ang II type-1 receptor blockade (AT1RB) attenuates left ventricle (LV) remodeling to a greater extent than angiotensin converting enzyme (ACE) inhibitor therapy and that the addition of xanthine oxidas...
What is the current status of trial NCT01052272?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 72 participants. The study started on 2005-07. Estimated completion is 2010-11.
What interventions are being tested in trial NCT01052272?
The interventions under investigation include: Allopurinol (DRUG), Ramipril (DRUG), Candesartan cilexetil (DRUG).
Who is sponsoring clinical trial NCT01052272?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.